News
NCNA
1.970
-6.19%
-0.130
Weekly Report: what happened at NCNA last week (0330-0403)?
Weekly Report · 04/06 10:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 04/02 21:05
NuCana files initial beneficial ownership statement for director Elliott Levy
Reuters · 04/01 20:33
Weekly Report: what happened at NCNA last week (0323-0327)?
Weekly Report · 03/30 10:01
NuCana files Form 3 initial beneficial ownership statement for Head of Translational Medicine David Harrison
Reuters · 03/24 20:21
Weekly Report: what happened at NCNA last week (0316-0320)?
Weekly Report · 03/23 09:57
NuCana plc director Martin C.B. Mellish files initial beneficial ownership statement
Reuters · 03/20 20:14
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 03/20 12:05
Unusual Machines, NuCana, Navigator Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga · 03/20 12:02
NuCana plc files Form 3 initial beneficial ownership statement for Chief Medical Officer Jeffrey D. Bloss
Reuters · 03/19 21:53
NuCana Posts 2025 Results, Highlights NUC-7738 Progress and Cash Runway Into 2029
TipRanks · 03/19 20:27
UK's NuCana Q4 net loss widens
Reuters · 03/19 20:25
NuCana GAAP EPS of $0.00
Seeking Alpha · 03/19 20:15
NuCana Q4 2025 EPS $0.00 and Revenue $0.00
Benzinga · 03/19 20:15
NuCana FY 2025 net loss widens 54.7% to GBP 29.4 million, Q4 net loss rises more than doubled to GBP 2.5 million
Reuters · 03/19 20:01
NuCana plc files Form 3 initial beneficial ownership statement for Interim CFO Ian Alexander Webster
Reuters · 03/18 21:40
NuCana plc files Form 3 initial beneficial ownership statement for director Kay Andrew Martin
Reuters · 03/18 21:37
NuCana plc COO Theresa Bruce files initial beneficial ownership statement
Reuters · 03/18 21:28
NuCana CEO and Director Hugh Griffith files initial beneficial ownership statement
Reuters · 03/18 21:25
Clearpoint Neuro, Valneva, Rocket Lab And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga · 03/18 12:02
More
Webull provides a variety of real-time NCNA stock news. You can receive the latest news about Nucana through multiple platforms. This information may help you make smarter investment decisions.
About NCNA
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.